Nuvalent, Inc. NUVL Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Direct Expenses Related To Program by Product | |||
| Discovery Programs | $11.88M+29.4% | $9.18M+6.9% | |
| Neladalkib | $105.45M+55.6% | $67.78M+113% | |
| NVL-330 | $21.82M+163% | $8.29M-22.0% | |
| Zidesamtinib | $59.52M-4.2% | $62.11M+123% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Nuvalent, Inc. break its business down?
- Nuvalent, Inc. (NUVL) reports direct expenses related to program by product across 4 parts — Discovery Programs, Neladalkib, NVL-330 and Zidesamtinib. Each is extracted from the segment footnotes and tracked over time.
- Where does Nuvalent, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Nuvalent, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.